Cargando…

CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer

SIMPLE SUMMARY: Pancreatic cancer is the fourth leading cause of cancer-related death in Western countries. Although several therapeutic strategies have been developed for pancreatic cancer, radiation therapy has not yet yielded satisfactory results. Unraveling the mechanism of radioresistance in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lan, Bin, Zeng, Siyuan, Zhang, Shuman, Ren, Xiaofan, Xing, Yuming, Kutschick, Isabella, Pfeffer, Susanne, Frey, Benjamin, Britzen-Laurent, Nathalie, Grützmann, Robert, Cordes, Nils, Pilarsky, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773906/ https://www.ncbi.nlm.nih.gov/pubmed/35053488 http://dx.doi.org/10.3390/cancers14020326

Ejemplares similares

Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer
por: Zhang, Jinping, et al.
Publicado: (2023)

Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer
por: Yang, Hai, et al.
Publicado: (2022)

Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator
por: He, Hang, et al.
Publicado: (2022)

CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
por: Zeng, Siyuan, et al.
Publicado: (2022)

CRISPR/Cas9-Mediated Knock-Out of Kras(G12D) Mutated Pancreatic Cancer Cell Lines
por: Lentsch, Eva, et al.
Publicado: (2019)

An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer
por: Yun, Duo, et al.
Publicado: (2022)

CRISPR Cas9 in Pancreatic Cancer Research
por: Yang, Hai, et al.
Publicado: (2019)

The Role of Exosomes in Pancreatic Cancer
por: Lan, Bin, et al.
Publicado: (2019)

Chemoresistance in Pancreatic Cancer
por: Zeng, Siyuan, et al.
Publicado: (2019)

A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
por: Chen, Xin-Zhu, et al.
Publicado: (2022)

Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma
por: Liu, Xiao, et al.
Publicado: (2023)

Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A
por: Widowati, Esti Wahyu, et al.
Publicado: (2018)

Feedback within the Inter-Cellular Communication and Tumorigenesis in Carcinomas
por: Rückert, Felix, et al.
Publicado: (2012)

Serum Tumor Markers in Pancreatic Cancer—Recent Discoveries
por: Rückert, Felix, et al.
Publicado: (2010)

DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B
por: Yousefelahiyeh, Mina, et al.
Publicado: (2018)

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B
por: Papenfuss, Marco, et al.
Publicado: (2022)

Emerging roles of DYRK2 in cancer
por: Tandon, Vasudha, et al.
Publicado: (2021)

Contribution of Blood Vessel Activation, Remodeling and Barrier Function to Inflammatory Bowel Diseases
por: Britzen-Laurent, Nathalie, et al.
Publicado: (2023)

Cas6 specificity and CRISPR RNA loading in a complex CRISPR-Cas system
por: Sokolowski, Richard D., et al.
Publicado: (2014)

Molecular Pathogenesis of Pancreatic Neuroendocrine Tumors
por: Ehehalt, Florian, et al.
Publicado: (2010)

c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer
por: Lux, Alexander, et al.
Publicado: (2019)

CRISPR/Cas-based customization of pooled CRISPR libraries
por: Kweon, Jiyeon, et al.
Publicado: (2018)

Anti‐CRISPRs: The natural inhibitors for CRISPR‐Cas systems
por: Zhang, Fei, et al.
Publicado: (2019)

One-carbon cycle alterations induced by Dyrk1a dosage
por: Delabar, Jean-Maurice, et al.
Publicado: (2014)

Special focus CRISPR-Cas
por: Marchfelder, Anita
Publicado: (2013)

What is CRISPR/Cas9?
por: Redman, Melody, et al.
Publicado: (2016)

CRISPR-Cas in Streptococcus pyogenes
por: Le Rhun, Anaïs, et al.
Publicado: (2019)

Advances in CRISPR/Cas9
por: Zhu, Youmin
Publicado: (2022)

CRISPR-Cas-Integrated LAMP
por: Atçeken, Nazente, et al.
Publicado: (2022)

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2023)

The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
por: Qiao, Huanhuan, et al.
Publicado: (2021)

The Omnipresence of DYRK1A in Human Diseases
por: Deboever, Estelle, et al.
Publicado: (2022)

Pre-clinical Models of Metastasis in Pancreatic Cancer
por: Miquel, Maria, et al.
Publicado: (2021)

CaSilico: A versatile CRISPR package for in silico CRISPR RNA designing for Cas12, Cas13, and Cas14
por: Asadbeigi, Adnan, et al.
Publicado: (2022)

The application of CRISPR/Cas9 system in cervical carcinogenesis
por: Gao, Chun, et al.
Publicado: (2021)

CRISPR/Cas9-Mediated Mutagenesis of RCO in Cardamine hirsuta
por: Alvim Kamei, Claire Lessa, et al.
Publicado: (2020)

Anti-CRISPR Phages Cooperate to Overcome CRISPR-Cas Immunity
por: Landsberger, Mariann, et al.
Publicado: (2018)

Not all predicted CRISPR–Cas systems are equal: isolated cas genes and classes of CRISPR like elements
por: Zhang, Quan, et al.
Publicado: (2017)

Divergent methylation of CRISPR repeats and cas genes in a subtype I-D CRISPR-Cas-system
por: Scholz, Ingeborg, et al.
Publicado: (2019)

Structural and functional characterization of Cas2 of CRISPR-Cas subtype I-C lacking the CRISPR component
por: Anand, Vineet, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_03q9o1rnssr3k7io13hp3ugbd2